Key Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$540 Hold
9
– – ﹤0.01% 1222
2026
Q2
$515 Hold
9
– – ﹤0.01% 1266
2026
Q1
$508 Hold
9
– – ﹤0.01% 1305
2025
Q4
$535 Hold
9
– – ﹤0.01% 1323
2025
Q3
$494 Hold
9
– – ﹤0.01% 1340
2025
Q2
$495 Hold
9
– – ﹤0.01% 1328
2025
Q1
$636 Hold
9
– – ﹤0.01% 1264
2024
Q4
$592 Hold
9
– – ﹤0.01% 1272
2024
Q3
$633 Hold
9
– – ﹤0.01% 1237
2024
Q2
$741 Hold
9
– – ﹤0.01% 1212
2024
Q1
$786 Hold
9
– – ﹤0.01% 1200
2023
Q4
$868 Hold
9
– – ﹤0.01% 1199
2023
Q3
$796 Hold
9
– – ﹤0.01% 1215
2023
Q2
$780 Hold
9
– – ﹤0.01% 1262
2023
Q1
$875 Hold
9
– – ﹤0.01% 1051
2022
Q4
$763 Hold
9
– – ﹤0.01% 1062
2022
Q3
$1K Hold
9
– – ﹤0.01% 1004
2022
Q2
$1K Hold
9
– – ﹤0.01% 988
2022
Q1
$1K Hold
9
– – ﹤0.01% 981
2021
Q4
$1K Hold
9
– – ﹤0.01% 867
2021
Q3
$1K Sell
9
-91
-91% -$7.18K ﹤0.01% 845
2021
Q2
$8K Hold
100
– – ﹤0.01% 610
2021
Q1
$8K Hold
100
– – 0.01% 516
2020
Q4
$9K Buy
+100
New +$7.93K 0.01% 471

Other funds holding BMRN

Key Financial's BMRN Position: Q3 2026 in Review

Key Financial held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 9 shares worth $540. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

Key Financial first reported a position in BMRN in Q4 2020 and has held it in 24 quarters since. The position peaked at $9K in Q4 2020. 434 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Key Financial held 9 shares of BioMarin Pharmaceuticals worth $540 as of Q3 2026.
  • Key Financial left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Key Financial's portfolio in Q3 2026, its #1222 holding.
  • Key Financial first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • Key Financial's BioMarin Pharmaceuticals position peaked at $9K in Q4 2020.
  • 434 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Key Financial's 13F filing for Q3 2026, filed 2 Nov 2026.